| |
Biovail 3Q profit falls 17 percent on costs
53 minutes ago (AP)
Drugmaker Biovail Corp. said Thursday its third-quarter profit fell 17 percent, mainly on costs related to the buyout of Prestwick Pharmaceuticals over a year ago and for commercialization rights to several drugs.
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 15B | | Price
/ Earnings: | 28.7 | | Price
/ Book: | 27.9 | | Net
Profit Margin (mrq): | 8.4% | | Price
To Free Cash Flow (mrq): | 60.7 | | Return
on Equity: | 12.6% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.4% |
|